engleski

Treatment with a glucagon-like peptide-1 receptor agonist exenatide decreases systolic blood pressure in overweight type 2 diabetic patients

Glucagon-like peptide-1 (GLP-1)agonists are increasingly used in the management of type 2 diabetes mellitus (T2DM), but their long- termcardiovascular safety is not yet confirmed. Therapy with GLP-1 receptor agonist exenatide has been associated with improvements in systolic blood pressure(SBP)and with small increases in heart rate(HR)in long-term clinical trials. In the present study, we assessed effects of exenatide on SBP, diastolic blood pressure(DBP)and HR in overweight T2DM. The findings of this study compare well with previous studies and suggest that 22-months administration of exenatide resulted in significant reduction in SBP in overweight T2DM. Experimental studies of GLP-1 analogues have also reported direct effects on blood pressure, possibly via interaction with the autonomic nervous system.

glukagon-like peptide-1; blood pressure; heart rate

nije evidentirano